Hepatitis C virus (HCV) is the main causative agent of chronic liver diseases that accounting for significant morbidity and mortality worldwide. Screening for HCV antigens presents an alternative marker to viral antibodies and RNA. Thus, this work aimed to detect HCV-E1 antigen level in different liver fibrosis stages and to evaluate the possible relationship between this level and the disease severity. The study was performed among one-hundred and forty one participants categorized into two groups (35 healthy individual and 106 chronic hepatitis C patients). All involved patients were recruited from Tropical Medicine Department, Mansoura University Hospitals, Mansoura, Egypt. HCV-E1 antigen was identified using western blotting and its level was quantified by ELISA. Fibrosis was staged according to METAVIR scoring system as the following: patients with fibrosis stage F1: 32.1% (34/106) of cases, F2: 29.2% (31/106) of cases, F3: 20.8% (22/106) of cases and F4: 19.7% (19/106) of cases. HCV-EI was identified at 38 kDa using their respective specific monoclonal antibody. HCV-EI antigen level (OD) significantly increased (P> 0.0001) with liver fibrosis progression, it was 0.77±0.27, 0.55±0.17,0.43 ±0.16, and 0.30 ±0.09, in F4, F3,F2, and F1;respectively.  HCV-EI antigen level seems to be associated with progression of HCV infection. It could be served as a good supplemental assay for HCV-RNA and could be used to diagnose active HCV infection.